More From Our Sponsor:
Apexus

SPONSORED CONTENT

The advancement of available technology solutions has 340B stakeholders turning to automation and artificial intelligence to support pharmacy operations such as inventory management, 340B claims qualification, and even auditing documentation. As technology continues to change, 340B Program leaders may want to leverage these

SPONSORED CONTENT

Consider the following scenario: A recent change in electronic health record billing at one of your outpatient clinics has led to accumulation errors in your 340B split-billing software, resulting in overpurchasing of 340B drugs. Although hypothetical, this scenario illustrates just one of many

SPONSORED CONTENT

Join Apexus at an upcoming webinar, Resolving 340B Noncompliance: From Reversals to Refunds, on Wednesday, January 15. This webinar will review different options available for resolving ineligible 340B purchases, including claim reversals, manufacturer repayments, and other options.

Our

SPONSORED CONTENT

Note: The Advanced 340B Operations Certificate Program is a separate Apexus offering that is not a part of the 340B Prime Vendor Program or otherwise associated with the Prime Vendor Agreement between HRSA and Apexus.

The

SPONSORED CONTENT

The Health Resources and Services Administration (HRSA) conducts randomized audits to assess compliance with the 340B drug pricing program, a federal initiative aimed at providing discounted medications to eligible entities. With more than 13,100 parent entities participating in

SPONSORED CONTENT

Resolving 340B noncompliance can be a time-consuming task for 340B participants — and one of the greatest challenges in managing a 340B program. This guide outlines the five steps to successfully navigate resolving compliance issues requiring repayment to manufacturers, from discovery to resolution,